Tracking Dengvaxia, Qdenga (TAK-003) & Tetravalent Dengue Vaccines
Updated July 2026. Dengue infects hundreds of millions each year across 129 countries, with cases surging due to climate change and urbanization. Three dengue vaccines are now licensed with meaningful global use: Qdenga (TAK-003) by Takeda — now approved in 43+ countries including India (July 2026) and WHO-prequalified since May 2024, with over 32 million doses distributed and no pre-vaccination screening required; Dengvaxia (CYD-TDV) by Sanofi (approved 2015, restricted to seropositive individuals aged 6–45 due to safety concerns — Sanofi has since announced global distribution discontinuation due to low demand); and Butantan-DV, Brazil's Butantan Institute's single-dose live-attenuated tetravalent candidate, approved domestically. All target four dengue serotypes (DENV-1 through DENV-4). The core clinical challenge remains antibody-dependent enhancement (ADE) — where prior infection or incomplete immunity can worsen subsequent infections — which is why serostatus-agnostic vaccines like Qdenga were a major breakthrough. This tracker monitors licensed vaccines, deployment programs, and next-generation candidates including single-dose tetravalent vaccines.